ANXA2 and hepatocellular carcinoma: A recent study by Sobolewski et al 39 utilized a proteomic approach and suggested that S100A11/ANXA2 overexpression was a hallmark of liver inflammation/fibrosis and associated with high-grade HCC and poor clinical outcomes.